A study on different therapies and prognosis-related factors for 101 patients with SCLC and brain metastases

Figures & data

Table 1. Characteristics o f 101 SCLC patients with brain metastases.

Clinical features	Number (n)	percentage
age
≤ 65	90	89.10%
>65	11	10.89%
gender
male	73	72.28%
female	28	27.72%
Stage when first visit
Local stage	55	54.45%
extensive stage	46	45.55%
PS score
0	7	6.93%
1	76	75.25%
2	17	16.83%
3	1	0.01%
Amount of brain metastases		81.19%
<3	19	18.81%
≥ 3	82	81.19%
Symptomatic brain metastases
yes	62	61.39%
no	39	28.61%
Other organ metastasis
yes	44	43.56%
no	57	56.44%
Lymph node metastasis
yes	78	77.23%
no	23	22.77%

Table 2. Recent and long-term curative effects for the treatment of brain metastasis lesions ineach group.

Treatment model	CR	PR	SD	PD	RR rate	Median PFS (month)	Median OS (month)
brain radiotherapy combined with sequential chemotherapy group(n = 32)	2	16	12	2	56.25%	12.98 ± 8.99	21.03 ± 12.76
chemotherapy combined with sequential brain radiotherapy group(n = 16)	1	6	6	3	43.75%	13.13 ± 7.66	19.69 ± 8.92
brain radiotherapy group(n = 32)	3	9	17	3	37.5%	11.33 ± 8.12	15.86 ± 10.43
chemotherapy group(n = 21)	1	5	10	6	28.5%	8.56 ± 4.51	12.07 ± 5.80

Figure 1. Survival curve of different treatment methods of SCLC patients with brain metastases.

Table 3. Univariate analysis of overall survival to 101cases of SCLC patients with brain metastases.

Factor	Total (n = 101)	Median survival time (month)	P value
sex			0.146
male	73	16.75 ± 9.24
female	28	18.79 ± 13.93
age			0.375
<65	84	17.11 ± 10.77
≥ 65	17	18.56 ± 10.97
PS score			0.049
1	96	18.38 ± 11.27
2	5	12.62 ± 7.74
stage			0.001
Local stage	57	20.55 ± 11.37
extensive stage	44	13.17 ± 8.23
Baseline blood sodium			0.918
normal	79	17.61 ± 9.10
low	22	18.56 ± 10.97
Baseline NSE			0.028
normal	28	21.23 ± 14.02
high	73	15.97 ± 8.86
Different treatment patterns			0.003
brain radiotherapy combined with sequential chemotherapy group	32	21.03 ± 12.76
chemotherapy combined with sequential brain radiotherapy group	16	19.69 ± 8.92
brain radiotherapy group	32	15.86 ± 10.43
chemotherapy group	21	12.07 ± 5.80
Whether brain metastasis during initial treatment			0.000
with	28	10.59 ± 5.26
without	73	19.90 ± 11.16
Whether chemotherapy when brain metastasis			0.017
yes	54	19.51 ± 11.11
no	47	14.45 ± 9.55
Focus number of brain metastases			0.395
<3	19	19.21 ± 10.60
≥ 3	82	16.88 ± 10.75

Table 4. Multivariate analysis of prognosis in patients with SCLC brain metastases.

	B	Wald	P	Exp (B)
sex	.043	.032	.858	1.044
age		3.745	.154
PS score		2.391	.495
stage		11.232	.004
Whether brain metastasis when initial visit	3.169	15.705	.000	23.786
Symptomatic brain metastases		8.025	.018
Baseline serum NSE		7.696	.021
Baseline serum sodium		3.943	.139
Brain radiotherapy and chemotherapy model		1.752	.625
First-line chemotherapy PFS	−.200	16.485	.000	.819
Radiation chemotherapy for brain metastases	.508	.228	.633	1.662
Brain metastases part PFS	−.092	6.190	.013	.912
PFS	−.086	4.937	.026	.917